Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN-D0501 in obese participants
2026-525869-42-00Phase 2Authorised
- Sponsor
- Pila Pharma
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing XEN-D0501 with Placebo (2 arms). Primary endpoints: Safety and tolerability: adverse events and Safety and tolerability: clinical measurements. Planned start Aug 2026; status: authorised.
02
Drugs
XEN-D0501
03
Conditions
obesity
Beyond the preview
Go deeper on 2026-525869-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525869-42-00.